Apogee Therapeutics Inc. Common Stock (APGE)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-09-03 close of $135.07, Apogee is a $6.7 billion market-cap biotech with no commercial-stage certainty visible in the figures. It is developing biologic therapies for immunological and inflammatory diseases, including ZUMILOKIBART and several other antibody candidates. Biotech can produce wonderful moats through patented medicines, but until approvals and sales exist, a moat is a hope, not a fact. The balance sheet shows very little debt, with D/E of 0.01, which is a genuine positive; an Altman Z-Score of 28.41 also suggests low near-term solvency risk by that model. But cash burn is real: trailing free cash flow is -$244.0M, a -3.7% FCF yield against the $6.7 billion market cap. FairStock's Piotroski F-Score is 1/9, and its overall FairStock Score is 26/100. Valuation looks demanding: P/B is 8.01 and P/E is -31.19, so there is no earnings anchor. The supplied profit growth figure is -29.89%, and there is no revenue growth figure to offset it. The stock sits near its 52-week high of $135.09, having ranged from $51.80 to $135.09, with beta 0.69. FairStock assigns no Lynch category because only 0 years of filed results are available and 3 are needed. Graham would demand a margin of safety; here the margin depends entirely on clinical and regulatory outcomes. I would want evidence of durable cash, trial success, and eventual revenue before calling this a value investment. The business may be promising, but the current numbers offer little defensive support.

In plain English: Apogee Therapeutics is a biotechnology company working on antibody treatments for immune and inflammatory diseases. On the figures provided, the business looks weak today because it is not profitable, burns cash, and has no revenue growth figure to judge. At the 2026-09-03 close of $135.07, the stock trades near the top of its 52-week range and looks expensive relative to current profits and accounting value, so the story depends on future pipeline success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-03 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer